SAB Biotherapeutics (SABS) Stock Statistics & Valuation Metrics

SAB Biotherapeutics has a market cap or net worth of $272.21M. The enterprise value is $19.58M.

SAB Biotherapeutics has 76,464,096 shares outstanding. The number of shares has decreased by -2.65% in one year.

SAB Biotherapeutics’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is -30.02%.

The current PE Ratio of SAB Biotherapeutics is ―. SAB Biotherapeutics’s PEG ratio is -0.05.

In the last 12 months, SAB Biotherapeutics had revenue of 0.00 and earned 13.27M in profits. Earnings per share was 0.22.

In the last 12 months, operating cash flow was -51.25M and capital expenditures -1.92M, giving a free cash flow of -53.17M billion.

SAB Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SAB Biotherapeutics upcoming earnings date is Aug 6, 2026, During Market Hours (Confirmed).

SAB Biotherapeutics as a current ratio of 9.46, with Debt / Equity ratio of 2.72%

In the past 12 months, SAB Biotherapeutics has paid 0.00 in taxes.

SAB Biotherapeutics EV to EBITDA ratio is 4.08, with an EV/FCF ratio of -1.48.

SAB Biotherapeutics has $107.39M in cash and marketable securities with $6.17M in debt, giving a net cash position of $101.22M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for SAB Biotherapeutics is $12.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy